Connect with us

Green Rush Daily

Cannabis Chewing Gum Is About To Get Even Better

Cannabis Chewing Gum Is About To Get Even Better

Business

Cannabis Chewing Gum Is About To Get Even Better

AXIM Biotechnologies was just granted the patent that covers any cannabinoid in its cannabis chewing gum products, including THC.

Award-Winning Cannabis Chewing Gum About To Get Even Better

AXIM Biotechnologies, Inc. is a world leader in cannabinoid research and development. Recently, the company made a major announcement about the future of its products. You probably haven’t heard of AXIM Biotech but they’re the company that owns the patent on using chewing gum as a delivery method for cannabidiol, or CBD. However, the company has just issued a statement that the US Patent and Trademark Office (USPTO) granted AXIM the patent that covers any cannabinoids both natural and synthetic in its medical chewing gum products, including THC.

Poised to Be A Leader In Cannabis Chewing Gum

AXIM built its reputation on its flagship product, CanChew® chewing gum. However, CanChew gum includes exclusively cannabidiol, or CBD. CBD is a prominent cannabinoid linked to several of the major medical benefits of cannabis. CanChew is unique for several reasons. First, it is a plant-based chewing gum made from industrial hemp extracted CBD. Second, the new gum formulated by AXIM, named CanChew Plus™ is the only gum that has a controlled-release of cannabinoids functional delivery system. The chewer absorbs CBD through their oral mucosa. This product uses pharmaceutical-grade, 99.9% pure CBD crystals, and is available in several concentrations. CanChew has won awards for its cannabis delivery system, and received praise because it is

  • non-habit forming
  • obtainable without a prescription
  • available in all 50 states and 40 countries worldwide
  • great-tasting without artificial ingredients
  • non-GMO, vegan, kosher, and gluten free

The new patent AXIM just obtained allows their chewing gum products to be delivery methods for any and all cannabinoids, including THC.

Additionally, AXIM is about to begin clinical trials with a new gum product called MedChew Rx. MedChew Rx will contain both CBD and THC in equal proportions. Indeed, the company is intending MedChew Rx as a treatment for pain and spasticity associated with multiple sclerosis. Currently, other cannabis products exist for treating MS, but none are in a chewing gum form. The estimated market size for this product is $4.8 billion.

The Future of Cannabis Chewing Gum

AXIM’s applied for the patent to include all cannabinoids in its chewing gum product back in April 2015. Now, it has officially been granted US Patent 9,433,601. The CEO of AXIM Biotech George E. Anastassov (MD, DDS, MBA) had this to say about his company’s latest development:

This new patent is paramount for our company as it provides us with the intellectual property protection to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and
THC, into our multiple cannabinoid-containing controlled-release chewing gum products.

But Dr. Anastassov also explained how the patent would support his company’s mission to provide medical cannabis relief to patients suffering from a range of symptoms and conditions.

Acquiring this new patent is also strategically important for AXIM’s mission to find cannabinoid-derived solutions for health conditions with no known cure.

Furthermore, the company is now protected from other entities that may wish to develop rival products with the same chewing gum delivery system. The company is addressing conditions like Parkinson’s and Alzheimer’s disease, ADHD and PTSD, autism, chronic pain, psoriasis, eczema, glaucoma, IBS, IBD and Crohn’s disease, to name a few.

But that’s not all that AXIM has in store for cannabis-containing chewing gum. Their newest patent-pending innovation is something entirely new. AX-1602 is a transdermal delivery system which releases cannabigerol (CBG), the “stem-cell” cannabinoid. Currently, AX-1602 is undergoing clinical trials for its use in the treatment of psoriasis and atopic dermatitis.

Adam Drury

Adam is a staff writer for Green Rush Daily who hails from Corvallis, Oregon. He’s an artist, musician, and higher educator with deep roots in the cannabis community. His degrees in literature and psychology drive his interest in the therapeutic use of cannabis for mind and body wellness.

More in Business

To Top